SCHEMBL12316615

SCHEMBL12316615

CC(C)(C)OC(=O)N1CCC(Oc2cc3c(cc2Cl)C(=O)CCO3)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.54
NPBWR1 P48145 1/20 0.46
MCHR1 Q99705 1/20 0.46
PDE4B Q07343 3/20 0.43
PDE4D Q08499 3/20 0.43
PDE4A P27815 2/20 0.43
PDE4C Q08493 2/20 0.43
TOP2A P11388 1/20 0.43
KDM1A O60341 1/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
HRH3 Q9Y5N1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
CACNB4 O00305 1/20 0.40
CACNA1A O00555 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNG3 O60359 1/20 0.40
CACNA1F O60840 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316659 0.89 GPR119 (0.54) GPR119NPBWR1MCHR1PDE4BPDE4D
SCHEMBL12316612 0.86 PRMT5 (0.40) GPR119PDE4BPRMT5WDR77HRH3
SCHEMBL12316542 0.84 NPBWR1 (0.46) GPR119NPBWR1MCHR1PDE4BPDE4D
SCHEMBL12316596 0.83 GPR119 (0.55) GPR119NPBWR1MCHR1PRMT5WDR77
SCHEMBL12316697 0.83 GPR119 (0.49) GPR119NPBWR1MCHR1PDE4BPDE4D
SCHEMBL12316785 0.82 GPR119 (0.47) GPR119NPBWR1MCHR1PDE4BPDE4D
SCHEMBL12316613 0.82 HTR1A (0.40) PRMT5WDR77
SCHEMBL12316638 0.78 CSNK2A1 (0.43) PDE4BPDE4DPDE4APDE4C
SCHEMBL7727287 0.76 NPBWR1 (0.57) GPR119NPBWR1MCHR1PDE4BPDE4D
SCHEMBL16759524 0.75 PDE4B (0.55) GPR119NPBWR1MCHR1PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS SLC29A1, SLC29A2, SLC43A3 GPR119 349/4885NPBWR1 640/4885MCHR1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.